Low-molecular-weight-heparins: A review of literature

Vascular Disease Prevention

Volumn 5, Issue 3, 2008, Pages 190-199

  Antignani, Pier Luigi ^a,c   Goffredo, Costanza ^b   Pepe, Leonardo Lassandro ^b   Allegra, Claudio ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c NONE   (Italy)

Author keywords

Low molecular weight heparins; Prevention of venous thromboembolism; Treatment of venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; BEMIPARIN; BLOOD CLOTTING FACTOR 10; CERTOPARIN; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; TINZAPARIN; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DEPOLYMERIZATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG COST; DRUG HALF LIFE; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY FAILURE; LABORATORY TEST; LUNG EMBOLISM; MOLECULAR WEIGHT; OSTEOPOROSIS; OUTPATIENT CARE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 48749114002     PISSN: 15672700     EISSN: None     Source Type: Journal    
DOI: 10.2174/156727008785133755     Document Type: Review

References (92)

1. Weitz, JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-698.
2. Fareed J, Leong WL, Hoppensteadt DA, et al. Generic low-molecular-weight heparins: some practical considerations. Semin Thromb Hemost 2004; 30: 703-713.
3. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 188S-203S.
4. Turpie AG. Pharmacology of the low-molecular-weight heparins. Am Heart J 1998; 135: S329-S33.
5. Hirsh J, O'Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation 2007; 116: 552-560.
6. Hyers TM. Heparin and other rapidly acting anticoagulants. Semin Vasc Surg 2005; 18: 130-133.
7. Ottani F, Ferrini D, Di Pasquale G, Galvani M. Low-molecularweight heparins and acute coronary syndromes. Ital Heart J Suppl 2001; 2: 958-971
8. Morris TA. Low molecular weight heparins: background and pharmacology. Semin Respir Crit Care Med 2000; 21: 537-546.
9. Hirsh J, Weitz J. New antithrombotic agents. Lancet 1999; 353: 1431-1436.
10. Morris TA. Heparin and low molecular weight heparin: background and pharmacology. Clin Chest Med 2003; 24: 39-47.
11. Agnelli G, Sonaglia F. Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics. Haematologica 2002; 87: 757-777.
12. Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 2000; 26 (Suppl 1): 31-38.
13. Hunt D. Low-molecular-weight heparins in clinical practice. South Med J 1998; 91: 2-10.
14. Barrett JS, Hainer JW, Kornhauser DM, et al. Anticoagulant pharmacodynamics of tinzaparin following 175 IU/kg subcutaneous administration to healthy volunteers. Thromb Res 2001; 101: 243-254.
15. Barrett JS, Giliansky E, Hull RD, et al. Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. Int J Clin Pharmacol Ther 2001; 39: 431-436.
16. Howard PA. Dalteparin: a low-molecular-weight heparin. Ann Pharmacother 1997; 31: 192-203.
17. Pineo GF, Hull RD. Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases. Eur J Med Res 2004; 9: 215-224.
18. Reeves JH, Cumming AR, Gallagher L, O'Brien JL, Santamaria JD. A controlled trial of low-molecular-weight heparin (dalteparin) vs. unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med 1999; 27: 2224-2228.
19. Mismetti P, Quenet S, Levine M, et al. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis. Chest 2005; 128: 2203-2210.
20. Polkinghorne KR, McMahon LP, Becker GJ. Pharmacodynamic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am J Kidney Dis 2002; 40: 990-995.
21. Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM. Safety and efficacy of unfractionated heparin vs. enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003; 146: 33-41.
22. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med 1997; 337: 657-662.
23. Quinian DJ, McQuillan A, -Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism. A meta-analysis of randomised, controlled trials. Ann Intern Med 2004; 140: 175-183.
24. Hull RD, Raskob GE, Brant RF, et al. Low-molecular-weight heparin vs. heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med 2000; 160: 229-236.
25. Van Dongen CJJ, van den Belt AGM, Prins MH, Lensing AWA. Fixed dose subcutaneous low molecular weight heparins vs. adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2007, Issue 4, Art 10.1002/14651858.CD001100.pub2.
26. Simonneaus G, Sors H, Charbonnier B, et al. A comparison of low-molecular weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE study group. Tinzaparine or heparine standards: evaluations dans l'embolie pulmonaire. N Engl J Med 1997; 337: 663-669.
27. Hall RD, Raskob GE, Pineo GF, et al. Low-molecular weight heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med 2000; 160: 229-236.
28. Merli G, Sprio TE, Ofson CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001; 134: 191-202.
29. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107(suppl 1): I9-16.
30. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular- weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. Ann Intern Med 1999; 130: 800-809.
31. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Arch Intern Med 2000; 160: 181-188.
32. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100: 269-277.
33. Kearon C, Ginsberg JS, Julian JA, et al.; Fixed-Dose Heparin (FIDO) Investigators. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006; 296: 935-942.
34. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005; 365: 1163-1174.
35. Ho WK, Hankey GJ, Lee CH, Eikelboom JW. Venous thromboembolism: diagnosis and management of deep vein thrombosis. Med J Aust 2005; 182: 476-481.
36. Huet Y, Gouault-Heilmann M, Contant G. Treatment of acute pulmonary embolism by a low molecular weight heparin fraction. A preliminary study. Intensive Care Med 1987; 13: 126-130.
37. Thery C, Simonneau G, Meyer G, et al. Randomized trial of subcutaneous low-molecular weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study. Circulation 1992; 85: 1380-1389.
38. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med 1997; 337: 657-662.
39. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. N Engl J Med 1997; 337: 663-669.
40. Torbicki A, Pacho R, Jedrusik P, et al. Noninvasive diagnosis and treatment of a saddle pulmonary embolism - A case report in support of new trends in management of pulmonary embolism. Chest 1996; 109: 1124-1126.
41. Szeto CC, Wang AY, Lui SF, et al. Treatment of pulmonary embolism by subcutaneous low-molecular-weight heparin in a hemodialysis patient. Am J Nephrol 1998; 18: 325-328.
42. Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet 1998; 351: 1077-1080.
43. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998; 338: 1169-1173.
44. Taliani MR, Agnelli G, Prandoni P, et al.; Warfarin Optimal Duration Italian Trial (WODIT) Investigators. Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. J Thromb Haemost 2003; 1: 1730-1733.
45. Geerts WH, Pineo G, Heit J, et al. Prevention of venous thromboembolism: the 7th ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 338S-400S.
46. Mismetti P, Laporte S, Darmon JY, et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001; 88: 913-930.
47. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346: 975-980.
48. Kirkpatrick A, Rathbun S, Whitsett T, Raskob G. Prevention of central venous catheter-associated thrombosis: a meta-analysis. Am J Med 2007; 120: 901.e1-13.
49. Monreal M, Alastrue A, Ruli M, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices - prophylaxis with low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75: 251-253.
50. Couban S, Goodyear M, Burnell M, et al. A randomized double-blind placebo-controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer. Blood 2002; 100: 2769.
51. Reichart P, Kretzschmar A, Biakhov M, et al. A phase III double blind placebo-controlled study evaluating the efficacy and safety of daily low-molecular weight heparin (dalteparin sodium, Fragmin) in preventing catheter-related complications in cancer patients with central venous catheters. Proc Am Soc Clin Oncol 2002; 21: 1474.
52. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488.
53. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin vs. a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
54. Büller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. The Seventh ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 suppl): 401S-428S.
55. Bick RL. Cancer-associated thrombosis. N Engl J Med 2003; 349: 109-111.
56. Klerk CPW, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 2130-2135.
57. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999; 341: 793-800.
58. Eichinger S, Kyrle PA. Prevention of deep vein thrombosis in orthopedic surgery. Eur J Med Res 2004; 9: 112-118.
59. Goldhaber SZ, for the PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-879.
60. Strebel N, Prins M, Agnelli G, Buller HR. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 2002; 162: 1451-1456.
61. Hull RD, Pineo GF, Stein PD, et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med 2001; 161: 1952-1960.
62. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trial. Lancet 2001; 358: 9-15.
63. Scarvelis D, Wells PS. Diagnosis and treatment of deep-vein thrombosis. CMAJ 2006;175(9): 1087-1092
64. Rai R, Cohen H, Dave M, Regan L. Controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipids antibodies (or antiphospholipid antibodies). BMJ 1997; 314: 253-257.
65. Duley L, Henderson-Smart D, Knight M, King J. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. BMJ 2001; 322: 329-333.
66. Patnaik MM, Haddad T, Morton CT. Pregnancy and thrombophilia. Exp Rev Cardiovasc Ther 2007; 5: 753-765.
67. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of the genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340: 9-13.
68. Martinelli I, Taioli E, Cetin I, et al. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 2000; 343: 1015-1018.
69. Many A, Elad R, Yaron Y, Eldor A, Lessing JB, Kupferminc MJ. Third-trimester unexplained intrauterine fetal death is associated with inherited thrombophilia. Obstet Gynecol 2002; 99: 684-687.
70. Gris JC, Mercier E, Quere I, et al. Low-molecular-weight heparin vs. low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103: 3695-3699.
71. Dimitrakakis C, Papageorgiou P, Papageorgiou I, Antzaklis A, Sakarelou N, Michalas S. Absence of transplacental passage of the low molecular weight heparin enoxaparin. Haemostasis 2000; 30: 243-248.
72. Richter C, Sitzmann J, Lang P, Weitzel H, Huch A, Huch R. Excretion of low molecular weight heparin in human milk. Br J Clin Pharmacol 2001; 52: 708-710.
73. K/DOQI clinical practice guidelines for chronic renal disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002; 39(suppl 2): S1-46.
74. Boneu B, de Moerloose P. How and when to monitor a patient treated with low molecular weight heparin. Semin Thromb Haemost 2001; 27: 519-522.
75. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447-452.
76. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy 2001; 21: 218-234.
77. Dunn AS, Coller B. Out patient treatment of deep vein thrombosis: translating clinical trials into practice. Am J Med 1999; 106: 660-669.
78. Schulman S. Unresolved issues in anticoagulant therapy. J Thromb Haemost 2003; 1: 1464-1470.
79. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contra-indication to the use of low-molecular-weight heparin? Arch Intern Med 2002; 162: 2605-2609.
80. Hory B, Claudet MH, Magnette J, Bechtel P, Bayrou B. Pharmacodynamics of a very low molecular weight heparin in chronic renal failure. Thromb Res 1991; 63: 311-317.
81. Cadroy Y, Pourrat Y, Baladre MF, et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 1991; 63: 385-390.
82. Mismetti P, Laporte-Simitsidis S, Navarro C, et al. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low-molecular weight heparin (nadroparin). Thromb Haemost 1998; 79: 1162-1165.
83. Siguret V, Pautas E, Fevrier M, et al. Elderly patients treated with tinzaparin (InnohepR) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 2000; 84: 800-804.
84. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacodynamics and metabolism in humans. Haemostasis 1996; 26(Suppl 2): 24-38.
85. Cornelli U, Fareed J. Human pharmacodynamics of low molecular weight heparins. Semin Thromb Hemost 1999; 25(Suppl 3): 57-61.
86. Cestac P, Bagheri H, Lapeyre-Mestre M, et al. Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients. Drug Saf 2003; 26: 197-207.
87. Gerlach AT, Pickworth KK, Seth SK, et al. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 2000; 20: 771-775.
88. De Lissovoy G, Yusen RD, Spiro TE, et al. Cost for inpatients care of venous thrombosis: a trial of enoxaparin vs. standard heparin. Arch intern Med 2000; 160: 3160-3165.
89. Aujesky D, Smith KJ, Cornuz J, Roberts MS. Cost-effectiveness of low molecular-weight heparin for treatment of pulmonary embolism. Chest 2005; 128: 1601-1610.
90. Estrada CA, Mansfield CJ, Heudebert GR. Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep vein thrombosis. J Gen Intern Med 2000; 15: 108-115.
91. Lloyd AC, Aitken JA, Hoffmeyer UK, et al. Economic evaluation of the use of nadroparin in the treatment of deep-vein thrombosis in Switzerland. Ann Pharmacother 1997; 31: 842-846.
92. Avritcher EB, Cantor SB, Shih YC, et al. Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatients treatment of cancer patients with deep venous thrombosis. Support Care Cancer 2004; 12: 531-536.